Evidence map›Paper›PMID 30196512›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2018

The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic Antibodies.

Peter M Bowers, William J Boyle, Robert Damoiseaux

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Therapeutic Antibodies: An Overview.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  4. Article
  5. Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Peter M BowersClinical and Translational Science Institute, UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. pbowers@mednet.ucla.edu.
William J BoyleClinical and Translational Science Institute, UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Robert DamoiseauxDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

The engineering of antibodies and antibody fragments for affinity maturation, stability, and other biophysical characteristics is a common aspect of therapeutic development. Maturation of antibodies in B cells during the adaptive immune response is the result of a process called somatic hypermutation (SHM), in which the activation-induced cytidine deaminase (AID) acts to introduce mutations into immunoglobulin (Ig) genes. Iterative selection and clonal expansion of B cells containing affinity-enhancing mutations drive an increase in the overall affinity of antibodies. Here we describe the use of SHM coupled with mammalian cell surface display for the maturation of antibodies in vitro and the complementarity of these methods with the mining of immune lineages using next-generation sequencing (NGS).

Indexed as

AntibodiesAntibody AffinityAntigensBase SequenceCytidine DeaminaseFlow CytometryHEK293 CellsHumansProtein BindingSomatic Hypermutation, ImmunoglobulinAntibodiesAntigensCytidine DeaminaseAffinity maturationAntibodyComplementarity-determining region (CDR)Fluorescence-activated cell sorting (FACS)Heavy chain (HC)Light chain (LC)Somatic hypermutation (SHM)

Identifiers

PMID30196512
PMCPMC6497467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.